ITRT Team, Institute for Regenerative Medicine

The Institute for Regenerative Medicine at Centro Médico Teknon in Barcelona (ITRT) promotes the advancement of scientific knowledge and the application of innovative biopharmaceutical treatments composed of adult stem cells, plasma growth factors and biomaterials.

ITRT designs and conducts clinical trials and in vitro and animal models in collaboration with public and private institutions to create new therapeutic tools for injuries or diseases of the musculoskeletal system refractory to standard treatments. Evidence of this work can be found in their prolific research activity and teaching activities, their active participation in prestigious scientific forums and the increasing output of publications on the subject.

Since its founding in 2003,  ITRT has conducted nine clinical trials in which stem cells have been applied in difficult-to-treat disorders such as fractures that do not consolidate, known as  pseudarthrosis, osteonecrosis of the femoral head and lumbar disc disease, and in the treatment of osteoarthritis of the knee and peripheral jointswith stem cells.

These trials are considered to be pioneering and the published results serve as reference worldwide. Detailed information  on each trial can be found in the technical datasheets section, and the impact it has in the media is reflected in the press kit for this website.

ITRT operates in accordance with agreements made with the research teams of the following cell production laboratories:XCELIA, the advanced therapies unit of the Barcelona Blood and Tissue Bank, the Institute for Biology and Molecular Genetics (IBGM), a joint centre managed by the University of Valladolid and the Spanish National Research Council (CSIC), and HISTOCELL of Bilbao, in partnership with Laboratorios SALVAT.

Thanks to ITRT's efforts, more than 500 patients have already benefited from mesenchymal stem cell therapy. High success rates have been achieved, with no complications attributable to the cell product administered having been reported, meaning that this therapy can be safely practised in patients who fulfil the appropriate medical criteria subject to prior authorisation from and monitoring by the Spanish Agency of Medicines and Medical Devices.

Última actualización: 26/11/2019